Özet:

Purpose: Despite its high incidence and bad results, there is no specific treatment for the acute respiratory disorder (ARDS). Many pharmacological agents have been studied in a variety of studies, but the treatment options that have been proven to be effective are limited. The aim of our study is to determine the effect of methylprednison therapy in early ARDS on mortality and morbidity. Methods: 47 patients with ARDS who were applied mechanical ventilation (MV) between January 2008 and December 2012 were included in this study. Patients were divided into two groups: the methylprednisolone group (22 patients) and the control group (25 patients). Persons in the methylprednisolone group after the dose of 2 mg/kg of intravenous load on the first day, 2-15. They were given an infusion of 0.5 mg/kg every 6 hours of the day and 0.25 mg/kg of methylprednisolone every 6 hours of the 16-22 days. Results: Compared to the control group, the rate of deviation from the MV in the methylprednisolone group was significantly higher (p=0,005), the MV time was shorter (p=0,021) and the mortality rate was lower (p=0,013). In the analysis of Kaplan Meier, the chances of survival in the methylprednisolone group were significantly higher than the control group (p=0,022). In addition, the result of lung damage in the methylprednisolone group was lower, the result of multiple organ dysfunction syndrome and the C-reactive protein values were lower. However, there was no difference between the two groups on the day the ARDS developed, the time of the ARDS and the time of stay in the hospital. Result: In patients diagnosed with ARDS, our study has shown that early methylprednisolone treatment provides significant improvement in the pulmonary and extra pulmonary organ functions, increases the likelihood of departure from the MV and reduces mortality.

Anahtar Kelimeler: